In focus · trending topic

ZEJULA

12 stories · following the connections

TESARO Announces First-Quarter 2018 Operating Results

By Nasdaq OMXMay 3, 2018, 8:05 PM UTC

TESARO and Medison Enter Into Exclusive Distribution Agreement to Commercialize ZEJULA® in Israel

By Nasdaq OMXApr 11, 2018, 12:31 PM UTC

TESARO Announces Availability of ZEJULA® (niraparib) for Women With Recurrent Ovarian Cancer in Germany

By Nasdaq OMXDec 15, 2017, 9:00 AM UTC

TESARO Announces European Commission Approval of ZEJULA® for Women With Recurrent Ovarian Cancer

By Nasdaq OMXNov 20, 2017, 12:01 PM UTC

TESARO Receives Positive CHMP Opinion for ZEJULA®

By Nasdaq OMXSep 15, 2017, 11:45 AM UTC

TESARO Announces Nine Data Presentations at the 2017 European Society for Medical Oncology (ESMO) Annual Meeting

By Nasdaq OMXAug 25, 2017, 12:01 PM UTC

Tesaro Announces Presentations of Abstracts at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

By Nasdaq OMXMay 25, 2017, 8:19 PM UTC

Tesaro Announces Presentations of Abstracts at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

By Nasdaq OMXMay 25, 2017, 8:19 PM UTC